Brazil plans shake-up of clinical trial approval process
This article was originally published in Scrip
Executive Summary
The Brazilian regulatory agency, Anvisa, has drawn up two sets of proposals for streamlining and accelerating the processes for approving applications to conduct clinical trials of new drugs and medical devices. The proposals are open for public consultation until 11 September.